To promote BBB transcytosis and intracellular delivery to glioblastoma tumor cells, the nanogels were also postfunctionalized with a cross‐reactive material 197 (CRM‐197), which is a clinically approved ligand addressing the diphtheria toxin receptor (DTR). The gene discussed is HBEGF; the disease is neoplasm.